Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

verubecestat

- PMLiVE

MSD and Astex announce expansion to oncology drug discovery collaboration

Astex will receive $35m upfront plus milestone payments totalling $500m per programme

- PMLiVE

Alzheimer’s Research UK awards £370,000 to University of Exeter researchers

The grants are part of a wider £3m funding announcement that aims to accelerate effective treatments for dementia

- PMLiVE

Quest Diagnostics launches Alzheimer’s blood test for US consumers

Alzheimer's disease is expected to affect around 14 million people in the US by 2060

- PMLiVE

Merck’s Keytruda combination shows promise in late-stage breast cancer study

More than 290,000 people are expected to be diagnosed with breast cancer in the US this year

- PMLiVE

Merck’s investigational pneumococcal vaccine shows promise in older adults

V116 is designed to address the strains that represent adult pneumococcal disease

- PMLiVE

Moderna and Merck’s skin cancer vaccine enters late-stage development

More than 1,000 patients with resected high-risk melanoma will be enrolled in the trial

- PMLiVE

Alliance for Genomic Discovery announces its five founding biopharma members

The AGD aims to accelerate drug development and expand the diversity of genomic data

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as a subcutaneous formulation

Leqembi was granted traditional approval in the US earlier this month as a bi-weekly intravenous infusion

- PMLiVE

Eli Lilly’s Alzheimer’s drug confirmed to significantly slow disease progression

The full phase 3 results presented at AAIC reinforce the cognitive benefits of donanemab

- PMLiVE

Alnylam presents promising results for RNAi therapeutic in Alzheimer’s disease at AAIC

ALN-APP is the first investigational RNAi therapeutic to show gene silencing in the human brain

- PMLiVE

Acumen shares positive results for investigational Alzheimer’s disease therapy at AAIC

The results will be discussed with regulators to assess next steps for clinical development

- PMLiVE

BMS obtains global rights to Prothena’s Alzheimer’s drug in deal worth $2.2bn

The decision comes two years after the company paid $80m for opt-in rights to PRX005

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links